Non-Metastatic Prostate Cancer Market Projected to Reach 4% Annual Growth

The oncology landscape is undergoing a fundamental transition as treatment strategies move away from conventional androgen deprivation and chemotherapy toward targeted, mechanism-driven therapies. This evolution is supported by the widespread adoption of next-generation imaging, specifically prostate-specific membrane antigen positron emission tomography, which allows for earlier and more precise disease identification. With 386,000 diagnosed prevalent cases recorded in 2025 across the seven major markets, the pressure to refine clinical outcomes has catalyzed an influx of novel pipeline candidates.

Pharmaceutical developers, including Janssen Research & Development, Candel Therapeutics, and Amgen, are currently advancing therapies designed to address specific disease characteristics. Notable assets such as Relugolix, CAN-2409, and Xaluritamig are central to these efforts, aiming to improve patient stratification and long-term efficacy. While emerging candidates seek to capture market share, XTANDI is expected to maintain its position as the top revenue-generating therapy through 2036. The United States remains the dominant market force, benefiting from robust screening practices and a high uptake of advanced clinical interventions compared to the EU4, the United Kingdom, and Japan.